FIG. 6. Effect of peptides and FN antibody on gastrulation. (a) Dorsolateral view of stage 13 control embryos, with closed blastopore (arrow) or small remnant of yolk plug (arrowhead). (b) Pear-shaped embryos incubated in 4 mg/ml of GRGDSP peptide, with protruding vegetal yolk mass (arrowheads); lateral view with dorsal side down (left) or up (right) at stage 13. (c) Embryo in 8 mg/ml of GRGDSP peptide, with large external vegetal yolk mass (arrowhead), dorsolateral view, stage 13. (d) Embryos incubated in 16 mg/ml of GRGESP control peptide, showing varying degrees of gastrulation abnormalities at stage 13, ranging from a slight delay of blastopore (arrow) closure (left), to a medium-sized (right), to a large (center) protruding yolk mass (arrowheads). (Arrows) Blastopore lip. Left and right embryo in approximately dorsal view, and center embryo in lateral view, dorsal side to the left. (a–d) All same magnification; bar, 500 mm. (e) Pearshaped stage 13 embryo incubated in 25 mg/ml of Fab fragments of FN antibody. Protruding yolk mass (arrowhead); blastopore lip (arrow). (f) Control embryo incubated in 50 mg/ml of IgG from preimmune serum, blastopore lip (arrow) nearly closed, small internalized yolk plug visible (arrowhead). (e and f) Same magnification; bar, 500 mm.
Image published in: Winklbauer R and Keller RE (1996)
Copyright © 1996. Image reproduced with permission of the Publisher, Elsevier B. V.
Permanent Image Page
Printer Friendly View
XB-IMG-145915